論文・総説 - 山本　正英

1. Keisuke Tanaka, Atsushi Takahata, Yuma Noguchi, Keigo Okada, Tatsuya Saito, Junichi Mukae, Yuki Osada, Ken Suzuki, Daisuke Mizuchi, Koh Yamamoto, Takashi Kumagai, Gaku Oshikawa, Takehiko Mori, Shigeo Toyota, Masahide Yamamoto. Reduced-Dose Bendamustine as a First-Line Treatment of Follicular Lymphoma Is Associated With Poorer Prognosis. Cancer Med. 2026.03; 15 (3): e71702. ( PubMed, DOI )

2. Yu Yagi, Yusuke Kanemasa, Hideki Goto, Masahide Yamamoto, Kotaro Miyao, Maki Hagihara, Toshio Kitawaki, Tatsu Shimoyama, Ryo Hanajiri, Shinichi Makita, Go Yamamoto, Masatoshi Sakurai, Nobuharu Fujii, Takahide Ara, Yasuhiro Nakashima, Akiyo Yoshida, Hideyuki Nakazawa, Emiko Sakaida, Nobuhiro Kanemura, Haryoon Kim, Keisuke Kataoka, Yoshiko Atsuta, Koji Kato. Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy. Bone Marrow Transplant. 2026.02; ( PubMed, DOI )

3. Junichi Mukae, Hiroki Akiyama, Keisuke Tanaka, Kota Yoshifuji, Ayako Nogami, Natsuka Umezawa, Yoshihiro Umezawa, Kouhei Yamamoto, Toshikage Nagao, Shinsuke Yasuda, Hirokazu Kanegane, Masatoshi Takagi, Takehiko Mori, Masahide Yamamoto. Classical Hodgkin lymphoma associated with immune deficiency and dysregulation exhibits a prognosis similar to sporadic cases but with distinct predictive markers. Ann Hematol. 2026.01; 105 (2): 48. ( PubMed, DOI )

4. Keisuke Tanaka, Hiroaki Kikuchi, Yoshihiro Umezawa, Takehiko Mori, Kiyohide Fushimi, Masahide Yamamoto. Management of inpatient chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell malignancies: an analysis using the Japanese Diagnosis Procedure Combination database. Int J Hematol. 2025.12; 122 (6): 856-863. ( PubMed, DOI )

5. Koji Kato, Jun Kato, Hideki Goto, Takeshi Kobayashi, Yoshiyuki Takahashi, Emiko Sakaida, Hidefumi Hiramatsu, Masahide Yamamoto, Satoshi Yoshihara, Jun Ando, Katsuyoshi Koh, Kentaro Fukushima, Fumiko Iwamoto, Ranjan Tiwari, Nobuharu Fujii. Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial. Cytotherapy. 2025.08; 27 (8): 938-943. ( PubMed, DOI )

6. Ikuyo Tsutsumi, Masahide Yamamoto, Takayuki Fujio, Nobuharu Kosugi, Gaku Oshikawa, Koh Yamamoto, Takasi Kumagai, Toru Miki, Daisuke Kudo, Shigeo Toyota, Yuichi Nakamura, Nobutaka Kawai, Masao Hagiwara, Takeshi Kobayashi, Ayako Arai, Takuya Komeno, Hiroshi Kojima, . A phase 2 trial of VRD induction for transplant-eligible Japanese patients with newly diagnosed multiple myeloma. Int J Hematol. 2025.05; ( PubMed, DOI )

7. Yu Uemura, Masahide Yamamoto, Masataka Ishimura, Hirokazu Kanegane, Akihisa Sawada, Akihiro Hirakawa, Ken-Ichi Imadome, Mayumi Yoshimori, Masashi Nagata, Kouhei Yamamoto, Norio Shimizu, Ryuji Koike, Ayako Arai. JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study. Blood Neoplasia. 2025.02; 2 (1): 100053. ( PubMed, DOI )

8. Yotaro Motomura, Kota Yoshifuji, Keisuke Tanaka, Chizuko Sakashita, Yoshihiro Umezawa, Toshikage Nagao, Sayuri Nitta, Yasuhiro Asahina, Takehiko Mori, Masahide Yamamoto. Hepatitis C virus-related hepatitis flare after immunochemotherapy in a patient with follicular lymphoma. J Clin Exp Hematop. 2024.12; 64 (4): 313-317. ( PubMed, DOI )

9. Momo Wakui, Junichi Tsuchiya, Chikara Kase, Kota Yokoyama, Masahide Yamamoto, Ukihide Tateishi. Comparative Study of Metabolic Tumor Volume in Multiple Myeloma and Related Plasma Cell Dyscrasias: 11C-Acetate PET vs. 18F-FDG PET. Cureus. 2024.10; 16 (10): e71605. ( PubMed, DOI )

10. Akiyama M, Kanayama M, Umezawa Y, Nagao T, Izumi Y, Yamamoto M, Ohteki T. An early regulatory mechanism of hyperinflammation by restricting monocyte contribution. Frontiers in immunology. 2024.07; 15 1398153. ( PubMed, DOI )

11. Umezawa Y, Yoshifuji K, Tanaka K, Nogami A, Nagano K, Tsuji A, Nagao T, Yamamoto M, Kajiwara M, Tohda S, Mori T. Impact of BK polyomavirus viremia on the outcomes of allogeneic hematopoietic stem cell transplantation. Annals of hematology. 2024.05; 103 (5): 1737-1744. ( PubMed, DOI )

12. Kawade G, Kurata M, Matsuki Y, Fukuda S, Onishi I, Kinowaki Y, Watabe S, Ishibashi S, Ikeda M, Yamamoto M, Ohashi K, Kitagawa M, Yamamoto K. Mediation of FSP1 expression via 4-HNE accumulation contributes to acquisition of resistance to apoptosis and ferroptosis in DLBCL. Laboratory investigation; a journal of technical methods and pathology. 2024.02; 102027. ( PubMed, DOI )

13. Hikaru Aoki, Yasunari Miyazaki, Tatsuhiko Anzai, Kota Yokoyama, Junichi Tsuchiya, Tsuyoshi Shirai, Sho Shibata, Rie Sakakibara, Takahiro Mitsumura, Takayuki Honda, Haruhiko Furusawa, Tsukasa Okamoto, Tomoya Tateishi, Meiyo Tamaoka, Masahide Yamamoto, Kunihiko Takahashi, Ukihide Tateishi, Tetsuo Yamaguchi. Deep convolutional neural network for differentiating between sarcoidosis and lymphoma based on [18F]FDG maximum-intensity projection images Eur Radiol. 2024.01; 34 (1): 374-383. ( PubMed, DOI )

14. Noriharu Nakagawa, Ken Ishiyama, Kensuke Usuki, Satoru Takada, Tatsuki Tomikawa, Hiroshi Handa, Yuna Katsuoka, Daiki Hirano, Nobuo Sezaki, Masahiko Sumi, Shin Fujisawa, Yasuhiro Taniguchi, Atsuko Mugitani, Takuro Yoshimura, Eiichi Ohtsuka, Ken Takase, Youko Suehiro, Shuichi Ota, Tomohiro Kajiguchi, Tomoya Maeda, Masahide Yamamoto, Shigeki Ohtake, Akira Katsumi, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki. Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT. Ann Hematol. 2024.01; 103 (1): 307-320. ( PubMed, DOI )

15. Motomura, Y; Yoshifuji, K; Tachibana, T; Takase, H; Arai, A; Tanaka, K; Okada, K; Nogami, A; Umezawa, Y; Sakashita, C; Yamamoto, M; Mori, T; Nagao, T. Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma BRITISH JOURNAL OF HAEMATOLOGY. 2023.12; ( PubMed, DOI )

16. Keisuke Tanaka, Ayako Ichikawa, Natsuka Umezawa, Kouhei Yamamoto, Kota Yoshifuji, Keigo Okada, Ayako Nogami, Yoshihiro Umezawa, Toshikage Nagao, Chizuko Sakashita, Takehiko Mori, Shuji Tohda, Ryuji Koike, Shinsuke Yasuda, Masahide Yamamoto. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis. Cancer Sci. 2023.09; 114 (9): 3719-3727. ( PubMed, DOI )

17. Masahide Yamamoto, Maho Sato, Yasushi Onishi, Yoji Sasahara, Hideki Sano, Masayoshi Masuko, Hirohisa Nakamae, Ken-Ichi Matsuoka, Takahide Ara, Kana Washio, Makoto Onizuka, Kenichiro Watanabe, Yoshiyuki Takahashi, Tsuneaki Hirakawa, Miwako Nishio, Chizuko Sakashita, Tohru Kobayashi, Akihisa Sawada, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Hashii, Yoshiko Atsuta, Ayako Arai. Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan. Am J Hematol. 2022.06; 97 (6): 780-790. ( PubMed, DOI )

18. Tsuyoshi Nakagawa, Kumiko Hayashi, Ayumi Ogawa, Goshi Oda, Iichiro Onishi, Masahide Yamamoto, Mio Mori, Tomoyuki Fujioka, Toshiaki Ishikawa, Kentaro Okamoto, Hiroyuki Uetake. Bone Marrow Carcinomatosis in a Stage IV Breast Cancer Patient Treated by Letrozole as First-Line Endocrine Therapy. Case Rep Oncol. 2022.04; 15 (1): 436-441. ( PubMed, DOI )

19. Hirohisa Nakamae, Masahide Yamamoto, Emiko Sakaida, Yoshinobu Kanda, Ken Ohmine, Takaaki Ono, Itaru Matsumura, Maho Ishikawa, Makoto Aoki, Akio Maki, Hirohiko Shibayama. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2022.01; 115 (1): 33-42. ( PubMed, DOI )

20. Yuji Sekine, Kouhei Yamamoto, Morito Kurata, Ayaka Honda, Iichiroh Onishi, Yuko Kinowaki, Genji Kawade, Shiori Watabe, Serina Nomura, Sho Fukuda, Sachiko Ishibashi, Masumi Ikeda, Masahide Yamamoto, Masanobu Kitagawa. HADHB, a fatty acid beta-oxidation enzyme, is a potential prognostic predictor in malignant lymphoma. Pathology. 2021.09; (21): 435-439. ( PubMed, DOI )